TY - JOUR
T1 - MIC-1 serum level and genotype
T2 - Associations with progress and prognosis of colorectal carcinoma
AU - Brown, David A.
AU - Ward, Robyn L.
AU - Buckhaults, Philip
AU - Liu, Tao
AU - Romans, Katharine E.
AU - Hawkins, Nicholas J.
AU - Bauskin, Asne R.
AU - Kinzler, Kenneth W.
AU - Vogelstein, Bert
AU - Breit, Samuel N.
PY - 2003/7/1
Y1 - 2003/7/1
N2 - Purpose: Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the tumor growth factor β (TGF-β) superfamily. Several observations suggest that it plays a role in colorectal carcinoma (CRC). In particular, MIC-1 is markedly up-regulated in colorectal cancers as well as in premalignant adenomas. This study examines the relationship of serum MIC-1 levels and genotypes to clinical and pathologic features of colonic neoplasia. Experimental Design: We confirmed the presence of MIC-1 in CRC tissue and the cell line CaCo-2. The normal range for serum MIC-1 levels was defined in 260 healthy blood donors, and the differences between normal subjects and 193 patients having adenomatous polyps or CRC were then determined. In a separate cohort of 224 patients, we evaluated the relationship of MIC-1 serum level and genotype to standard tumor parameters and outcome measures. Results: MIC-1 was expressed in CRC tissue and the cancer cell line CaCo-2. There was a progressive increase in serum MIC-1 levels between normal individuals [mean (M) = 495 pg/ml, SD = 210), those with adenomatous polyps (M = 681 pg/ml, SD = 410), and those with CRC (M = 783 pg/ml, SD = 491)]. Serum MIC-1 level was correlated with the extent of disease so that the levels were higher in patients with higher Tumor-Node-Metastasis stage. There were significant differences in time to relapse and overall survival between subjects with different MIC-1 levels and genotypes. Conclusions: This study identifies a strong association between MIC-1 serum levels and neoplastic progression within the large bowel. We suggest that the measurement of serum MIC-1 levels and determination of MIC-1 genotype may have clinical use in the management of patients with CRC.
AB - Purpose: Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the tumor growth factor β (TGF-β) superfamily. Several observations suggest that it plays a role in colorectal carcinoma (CRC). In particular, MIC-1 is markedly up-regulated in colorectal cancers as well as in premalignant adenomas. This study examines the relationship of serum MIC-1 levels and genotypes to clinical and pathologic features of colonic neoplasia. Experimental Design: We confirmed the presence of MIC-1 in CRC tissue and the cell line CaCo-2. The normal range for serum MIC-1 levels was defined in 260 healthy blood donors, and the differences between normal subjects and 193 patients having adenomatous polyps or CRC were then determined. In a separate cohort of 224 patients, we evaluated the relationship of MIC-1 serum level and genotype to standard tumor parameters and outcome measures. Results: MIC-1 was expressed in CRC tissue and the cancer cell line CaCo-2. There was a progressive increase in serum MIC-1 levels between normal individuals [mean (M) = 495 pg/ml, SD = 210), those with adenomatous polyps (M = 681 pg/ml, SD = 410), and those with CRC (M = 783 pg/ml, SD = 491)]. Serum MIC-1 level was correlated with the extent of disease so that the levels were higher in patients with higher Tumor-Node-Metastasis stage. There were significant differences in time to relapse and overall survival between subjects with different MIC-1 levels and genotypes. Conclusions: This study identifies a strong association between MIC-1 serum levels and neoplastic progression within the large bowel. We suggest that the measurement of serum MIC-1 levels and determination of MIC-1 genotype may have clinical use in the management of patients with CRC.
UR - http://www.scopus.com/inward/record.url?scp=12444303172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12444303172&partnerID=8YFLogxK
M3 - Article
C2 - 12855642
AN - SCOPUS:12444303172
SN - 1078-0432
VL - 9
SP - 2642
EP - 2650
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 7
ER -